Arkolith/Insider Trading/BCAX/Form 4

Mazumdar Claire

Chief Executive Officer, DirectorBicara Therapeutics Inc. (BCAX) · full profile →Form 4 · filed Apr 20, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$354K
Net Open-Market Flow
-$354K
Transactions
9
5 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 20, 2026Option exercise(M)15K$3.79$57K377K
Apr 20, 2026Sell(S)15K$23.61$354K362K
Apr 16, 2026Option exercise(M)7K$5.45$39K362K
Apr 16, 2026Option exercise(M)8K$4.44$36K348K
Apr 16, 2026Option exercise(M)7K$3.79$28K355K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 20, 2026Option exercise(M)15K—$0161K
Apr 16, 2026Option exercise(M)8K—$057K
Apr 16, 2026Option exercise(M)7K—$0131K
Apr 16, 2026Option exercise(M)7K—$0558K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-026089) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML